| First Author | Johnston RJ | Year | 2014 |
| Journal | Cancer Cell | Volume | 26 |
| Issue | 6 | Pages | 923-937 |
| PubMed ID | 25465800 | Mgi Jnum | J:217453 |
| Mgi Id | MGI:5614130 | Doi | 10.1016/j.ccell.2014.10.018 |
| Citation | Johnston RJ, et al. (2014) The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26(6):923-37 |
| abstractText | Tumors constitute highly suppressive microenvironments in which infiltrating T cells are "exhausted" by inhibitory receptors such as PD-1. Here we identify TIGIT as a coinhibitory receptor that critically limits antitumor and other CD8(+) T cell-dependent chronic immune responses. TIGIT is highly expressed on human and murine tumor-infiltrating T cells, and, in models of both cancer and chronic viral infection, antibody coblockade of TIGIT and PD-L1 synergistically and specifically enhanced CD8(+) T cell effector function, resulting in significant tumor and viral clearance, respectively. This effect was abrogated by blockade of TIGIT's complementary costimulatory receptor, CD226, whose dimerization is disrupted upon direct interaction with TIGIT in cis. These results define a key role for TIGIT in inhibiting chronic CD8(+) T cell-dependent responses. |
